Table 2:

Clinical and demographic characteristics of patients receiving different CMS dosage regimens.

Variable	< 3 million IU/day (n = 6)	≥ 3 million IU/day (n = 9)	≥ 6 million IU/day (n = 12)	≥ 9 million IU/ day (n = 6)	P
Age, years**	76 (70–85)	67 (44–82)	61 (46–77)	69 (52–85)	0.06
Male sex, n (%)	6 (100)	8 (88.9)	8 (66.7)	4 (66.7)	0.08
Charlson index**	8 (4–9)	5 (0–9)	4 (0–9)	6 (2–7)	0.3
Clinical status:  - Severe sepsis  - Shock	2 (33.3) 1(16.7)	3 (33.3) 0 (0)	3 (25) 0 (0)	2 (33.3) 0 (0)	0.86 0.18
1CMS total dose (million IU) *	20 (4–40)	24 (9–112)	24 (11–120)	30 (27–99)	0.20
1CMS treatment duration, days**	10 (5–20)	8 (3–28)	5 (3–20)	5 (3–11)	0.62
2GFR at baseline (mL/min/1.73 m2)**	33.4 (19–51)	96.9 (39–353)	107 (44–212)	122 (81–138)	0.005
3Css,avg (mg/L)**	0.85 (0.28–3.02)	0.57 (0.21–2.43)	1.1 (0.5–3.64)	1.4 (0.3–5.2)	0.16
4Expected Css,avg (mg/L)	0.51 (0.35–0.62)	0.46 (0.03–1.17)	0.83 (0.26–1.65)	1.04 (0.88–1.66)	0.05
5AUC/6MIC**	40.8 (12–145	27.4 (9.6–116.6)	42.7 (15.6–174.7)	67.2 (57.6 –249.6)	0.21
AUC/MIC > 60 mg∙h/L	2 (33.3)	1 (11.1)	5 (41.7)	3 (50)	0.37
Css,avg > 2.5 mg/L Css, avg above MIC	1 (16.7) 3 (50)	0 (0) 6 (66.7)	1 (8.3) 9 (75)	1 (16.7) 4 (66.7)	0.83 0.61
7AKI at 8EOT, n (%):  - R (Risk)  - I (Injury)  - F (Failure)	2 (33.3) 1 (50) 1 (50) 0 (0)	3 (33.3) 0 (0) 2 (66.6) 1 (33.3)	4 (33.3) 1 (25) 3 (75) 0 (0)	1 (16.7) 0 (0) 0 (0) 1 (100)	0.89
Clinical cure, n (%)	6 (100)	8 (88.9)	11 (91.7)	6 (100)	0.95
Microbiological eradication, n (%)	2 (50)	7 (87.5)	7 (87.5)	6 (100)	0.36

¹CMS: colistin methanesulfonate

²GFR: glomerular filtration rate

³C_ss,avg: colistin plasma concentration at steady-state

⁴Calculated C_ss,avg according the algorithm of Nation et al

⁵AUC: colistin area under the curve

⁶MIC: minimum inhibitory concentration

⁷AKI: acute kidney injury.